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Objectives This study was conducted to evaluate mineral metabolism markers as potential risk factors for calcific aortic
valve disease.
Background Mineral metabolism disturbances are common among older people and may contribute to cardiac valvular calci-
fication. Associations of serum mineral metabolism markers with cardiac valvular calcification have not been
evaluated in a well-characterized general population of older adults.
Methods We measured serum levels of phosphate, calcium, parathyroid hormone, and 25-hydroxyvitamin D in 1,938 Car-
diovascular Health Study participants who were free of clinical cardiovascular disease and who underwent echo-
cardiographic measurements of aortic valve sclerosis (AVS), mitral annular calcification (MAC), and aortic annu-
lar calcification (AAC). We used logistic regression models to estimate associations of mineral metabolism
markers with AVS, MAC, and AAC after adjustment for relevant confounding variables, including kidney function.
Results The respective prevalences of AVS, MAC, and AAC were 54%, 39%, and 44%. Each 0.5 mg/dl higher serum
phosphate concentration was associated with greater adjusted odds of AVS (odds ratio [OR]: 1.17, 95% confidence
interval [CI]: 1.04 to 1.31, p  0.01), MAC (OR: 1.12, 95% CI: 1.00 to 1.26, p  0.05), and AAC (OR: 1.12, 95% CI:
0.99 to 1.25, p  0.05). In contrast, serum calcium, parathyroid hormone, and 25-hydroxyvitamin D concentrations
were not associated with aortic or mitral calcification.
Conclusions Higher serum phosphate levels within the normal range were associated with valvular and annular calcification
in a community-based cohort of older adults. Phosphate may be a novel risk factor for calcific aortic valve dis-
ease and warrants further study. (J Am Coll Cardiol 2011;58:291–7) © 2011 by the American College of Cardi-
ology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.073Calcific aortic valve disease (CAVD) is a progressive con-
dition involving calcification and fibrosis of the aortic valve
leaflets. The disease sequence begins with aortic valve
sclerosis (AVS), in which the leaflets thicken and develop
microcalcification but do not obstruct left ventricular out-
flow. Progressive calcification and fibrosis result in obstruc-
tion to left ventricular outflow, which characterizes clinical
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epidemiological features with atherosclerosis (2–4). How-
ever, unlike atherosclerosis, there is no known effective
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a recent large randomized clinical
trial of lipid-lowering therapy
failed to reduce the progression
of aortic stenosis (5). Identifica-
tion of novel, modifiable risk fac-
tors remains an essential next
step in developing medical ther-
apies for valvular heart disease.
Disturbances in mineral me-
tabolism are common among
older adults (6,7), and prelimi-
nary evidence suggests a poten-
tial role in the pathogenesis of
cardiac valve calcification. In the
setting of kidney disease, in
which phosphate metabolism is
grossly disturbed, higher serum
phosphate concentrations are as-
sociated with aortic and mitral
valve calcification (8,9). Moreover, primary hyperparathy-
roidism is linked with aortic valve calcification (10), and
vitamin D receptor polymorphisms are associated with aortic
stenosis (11). These connections have not yet been evaluated in
a general population of older people without known kidney
impairment or hyperparathyroidism.
We tested the hypotheses that serum concentrations of
phosphate, parathyroid hormone, and 25-hydroxyvitamin D
(25-OHD) would be associated with AVS, mitral annular
calcification (MAC), and aortic annular calcification (AAC)
in a population-based cohort of ambulatory older adults.
Methods
Study population. We evaluated participants from the
CHS (Cardiovascular Health Study), a prospective
population-based cohort study of cardiovascular disease
among older adults. Details of the study design have been
published previously (12). Briefly, between 1989 and 1990,
CHS enrolled 5,201 ambulatory adults age 65 years from
4 U.S. communities (Forsyth County, North Carolina;
Washington County, Maryland; Sacramento County, Cal-
ifornia; and Pittsburgh, Pennsylvania). An additional 687
African Americans were enrolled between 1992 and 1993.
Exclusions from CHS included the use of a wheelchair,
institutionalization, inability to give informed consent, plans
to move away from the area within 3 years, or active
treatment for malignancy. Each participating center re-
ceived institutional review board approval, and all individ-
uals gave informed consent.
We studied CHS participants from the 1992 or 1993
examination who had available measurements of mineral
metabolism markers, which were performed as a part of a
different ancillary study of incident cardiovascular events.
Participants were excluded from the cardiovascular events
Abbreviations
and Acronyms
25-OHD  25-
hydroxyvitamin D
AAC  aortic annular
calcification
AVS  aortic valve
sclerosis
CAVD  calcific aortic
valve disease
CKD  chronic kidney
disease
eGFR  estimated
glomerular filtration rate
LDL  low-density
lipoprotein
MAC  mitral annular
calcification
PTH  parathyroid hormonestudy if they had a preexisting clinical history of any one of ithe following cardiovascular diseases: coronary artery dis-
ease, heart failure, aortic stenosis, stroke, claudication,
arrhythmia, or presence of a pacemaker or implantable
cardiac defibrillator. Cardiovascular conditions were deter-
mined by review of medical records, electrocardiographic
findings, and patient questionnaires (13). There were 4,692
individuals who attended the 1992 or 1993 CHS examina-
tion. A total of 1,428 participants were excluded because of
prevalent cardiovascular disease, 948 because of inadequate
serum volume to run the mineral metabolism measure-
ments, and 378 because of not completing an echocardio-
gram, leaving 1,938 participants for analysis.
Measurements. Mineral metabolism measurements were
performed using serum samples collected during the 1992 or
1993 CHS examination. Participants were asked to fast
before collection. Samples were stored at the Laboratory for
Clinical Biochemistry Research at the University of Ver-
mont using established methods to ensure long-term stabil-
ity (14) and were assayed at the University of Washington
Clinical Nutrition Research Unit Laboratory. Total 25-
OHD was measured on a Waters Quattro Micro mass
spectrometer (Waters Corp., Milford, Massachusetts) with
an interassay coefficient of variation 3.4%. Intact parathy-
oid hormone (PTH) was quantified with a 2-site immu-
oassay (Unicel DxI clinical analyzer, Beckman Coulter
nc., Brea, California) with a reference range of 17 to 66
g/ml. Phosphate levels were determined using a timed-rate
olorimetric reaction method with ammonium molybdate at
cidic pH and serum nonionized total calcium was mea-
ured using indirect potentiometry on a DxC Synchron
nalyzer (Beckman Coulter Inc.).
Trained CHS study personnel conducted standardized
nterviews to determine participant demographics, past
edical history, lifestyle factors, and medications. Blood
ressure was measured in triplicate 5 min apart. Prescription
edication use was ascertained from a review of prescription
ottle labels by interviewers. Lipid measurements were
ade at the Laboratory for Clinical Biochemistry Research,
nd low-density lipoprotein (LDL) levels were calculated
sing the Friedwalde equation. Estimated glomerular filtra-
ion rate (eGFR) was derived from cystatin C measurements
sing the equation: eGFR  76.7  (cystatin C)1.19 (15).
ypertension was defined as systolic blood pressure 140
m Hg, diastolic blood pressure 90 mm Hg, or use of
ntihypertensive medications. Diabetes was defined by fast-
ng glucose level 7.8 mmol/l (140 mg/dl) or the use of
diabetic medication.
chocardiography. Two-dimensional echocardiograms
ere recorded on videotape using an SSH-160A ultrasound
achine (Toshiba America Medical Systems Inc., Tustin,
alifornia) during the 1994 or 1995 CHS examination, as
etailed previously (16). The echocardiograms were evalu-
ted at a centralized core laboratory (Georgetown Univer-
ity, Washington, DC) by observers blinded to the partic-
pants’ clinical history.
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July 12, 2011:291–7 Phosphate and Valve CalcificationAVS, MAC, and AAC were defined based on previous
CHS studies (17,18). Aortic annulus (AAC) and leaflet
calcification (AVS) were considered separate outcomes be-
cause of their different cellular components and potential
calcification mechanisms. AVS was identified as aortic cusp
thickening with normal aortic cusp excursion and a peak
trans-aortic valve flow velocity2.0 m/s. MAC was defined
by an intense echocardiograph-producing structure lo-
cated at the junction of the atrioventricular groove and
posterior mitral leaflet on the parasternal long-axis,
short-axis, or apical 4-chamber view. The presence of
AAC was similarly defined as increased echodensity of
the aortic root at the insertions of the aortic cusps. For
167 participants, individual components of the aortic
valve evaluation (peak velocity, cusp excursion, or leaflet
thickness) were not evaluated or were considered to be
abnormal but did not meet the definition of AVS; these
individuals were excluded from AVS analyses. There
were 16 participants without assessment of MAC and 48
participants without evaluation of AAC who were ex-
cluded from analyses of these outcomes.
Statistical analysis. We evaluated mineral metabolism ex-
osure variables continuously and using previously pub-
ished categories (8). We analyzed AVS, MAC, and AAC
s binary outcome variables. We used linear regression to
xplore associations of covariates with the serum phosphate
oncentration (Online Tables). We used logistic regression
ith robust SE to estimate the association of each mineral
etabolism variable with the log odds ratio (OR) of each
inary outcome. We created nested multivariable models to
valuate an a priori set of potential confounding variables:
ge, sex, race, eGFR, hypertension, diabetes, smoking, body
ass index, LDL cholesterol, high-density lipoprotein cho-
esterol, statin use, serum calcium levels, and clinic site.
ndividual serum samples at each clinical site were collected
uring the same season, thus providing seasonally adjusted
stimates. We investigated potential nonlinear associations
sing cubic spline models for continuous mineral metabo-
ism covariates. There were 11 individuals who self-
dentified as an ethnicity other than Caucasian or African
merican; given the small number, these measurements
ere classified into the Caucasian strata when models were
djusted for race. Because of the high prevalence of AVS in
his population, OR did not approximate relative risk well;
hus, we additionally calculated adjusted proportions for
asier clinical interpretation.
We tested for whether sex, race, eGFR, and/or serum
alcium level modified associations of serum phosphorus
ith study outcomes using the Wald test. Given no statis-
ically significant interactions, these associations are pre-
ented as pooled analyses. We conducted a sensitivity
nalysis by excluding patients with overt hyperphos-
hatemia (4.5 mg/dl); this exclusion did not change
nferences. All analyses were conducted using Stata version
0.1 (Stata Corp., College Station, Texas). cResults
There were 1,938 individuals with serum phosphate mea-
surements and available echocardiogram data in this analy-
sis. Serum phosphate concentrations were normally distrib-
uted, 3.6  0.5 mg/dl. Overt hyperphosphatemia was rare
in this cohort. More than 97% of individuals had a serum
phosphate level below the upper limit of normal (4.5
mg/dl), and there were only 3 individuals who had a serum
phosphate level 5.0 mg/dl. Serum concentrations of 25-
OHD and PTH were 25.8  11.7 ng/ml and 56.0  28.8
pg/ml, respectively. Measurements consistent with primary
hyperparathyroidism (calcium 10 mg/dl and PTH 65
g/ml) were found in 25 participants (1%), and 304 indi-
iduals (16%) had 25-OHD deficiency (15 ng/ml).
The average age of the study population was 73.5 years.
he majority of participants were Caucasian, and the mean
GFR was 76.6 ml/min/1.73 m2 (Table 1). Excluded
atients without available measurements were more likely to
e older and male and have more comorbidities (Online
ables). In multivariable analysis, female sex had the stron-
est association with serum phosphate levels, which were on
verage 0.4 mg/dl greater among women. Additionally, LDL
holesterol level correlated directly with the serum phosphate
oncentration, whereas body mass index, systolic blood pres-
ure, eGFR, and PTH level were correlated inversely.
The respective prevalences of AVS, MAC, and AAC were
4%, 39%, and 44%. In unadjusted and demographic adjusted
odels, higher serum phosphate concentrations were associ-
ted with greater odds of each valvular calcification outcome
Table 2). Associations of serum phosphate levels with AAC
o longer reached statistical significance in fully adjusted
odels. The adjusted prevalences of AVS, MAC, and AAC
ere 12%, 11%, and 7% greater, comparing participants in the
ighest (4.0 mg/dl) versus lowest (3.0 mg/dl) serum
hosphate level categories. Associations of serum phosphate
evels with valve outcomes appeared to be generally linear (Fig. 1).
Serum concentrations of 25-OHD and PTH were not
ssociated with any of the valvular outcomes (Table 3, Fig. 2).
here was no association with calcium level and AVS (OR:
.93, 95% confidence interval [CI]: 0.70 to 1.25), MAC
OR: 1.24, 95% CI: 0.91 to 1.70), or AAC (OR: 1.02, 95%
I: 0.77 to 1.36). Exclusion of participants with primary
yperparathyroidism did not alter these results.
iscussion
n a community-based population of older adults without
nown cardiovascular disease, higher serum phosphate
evels that were elevated, but still within the normal
ange, were associated with AVS and MAC. Associations
f phosphate level with AAC also were observed but did
ot reach statistical significance after full adjustment.
he observed associations were independent of kidney
unction and PTH, calcium, and 25-OHD levels, all of
hich play biological roles in phosphate metabolism andalcification. Importantly, associations were not observed
rate; HD
294 Linefsky et al. JACC Vol. 58, No. 3, 2011
Phosphate and Valve Calcification July 12, 2011:291–7between PTH, calcium, or 25-OHD levels and calcifica-
tion outcomes.
To our knowledge, this study is the first to demonstrate
an association between serum phosphate levels and car-
diac valve calcification in a population-based cohort
without chronic kidney disease (CKD). A previous ret-
rospective cross-sectional study of patients with aortic
Baseline Characteristics of Participants by SeruTable 1 Baseline Characteristics of Particip
Characteristic
<3.0 mg/dl
(n  271)
Age, yrs 73.3 4.6
Men 174 (64.2)
Race
Caucasian 227 (84)
African American 44 (16)
Hypertension 170 (62.7)
Diabetes 39 (14.4)
Smoking (current or past) 153 (56.5)
Medication use
Antihypertensive 101 (37.3)
Statin 7 (2.6)
BMI, kg/m2 27.5 4.4
LDL, mg/dl 122.5 31.7
HDL, mg/dl 50.6 13.6
eGFR, ml/min/1.73 m2 77.7 18.9
Calcium, mg/dl 9.44 0.38
25-OHD, ng/ml 26.3 11.3
PTH, pg/ml 67.8 33.9
Values are mean  SD or n (%).
BMI  body mass index; eGFR  estimated glomerular filtration
parathyroid hormone; 25-OHD  25-hydroxyvitamin D.
Association of Serum Phosphate Concentration With Aortic Valve Sand Aor c Annular CalcificationTable 2 Association f Serum Phosphate Concentration With Aand Aortic Annular Calcification
Unadjusted
OR (95% CI) p Value
Aortic valve sclerosis, mg/dl
3.0 1.00 (reference)
3.1–3.5 1.11 (0.82–1.50)
3.6–4.0 1.23 (0.91–1.65)
4.0 1.44 (1.02–2.01)
per 0.5 1.12 (1.01–1.23) 0.03
Mitral annular calcification, mg/dl
3.0 1.00 (reference)
3.1–3.5 1.35 (1.00–1.82)
3.6–4.0 1.44 (1.07–1.94)
4.0 1.70 (1.22–2.38)
per 0.5 1.16 (1.06–1.30) 0.001
Aortic annular calcification, mg/dl
3.0 1.00 (reference)
3.1–3.5 1.03 (0.77–1.38)
3.6–4.0 1.27 (0.95–1.70)
4.0 1.40 (1.01–1.94)
per 0.5 1.14 (1.04–1.25) 0.006*Adjusted for age, sex, and race. †Adjusted for age, sex, race, eGFR, hypertension, diabetes, smoking, B
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.stenosis found an inverse relationship of phosphorus level
with aortic valve area on echocardiogram (19). Similarly,
a recent case-control study of referred patients with aortic
stenosis had a higher unadjusted level of phosphate than
that of age- and sex-matched controls (20). Phosphate
levels have been associated with calcification of coronary
arteries (21,22) and with incidence of future cardiovas-
osphate Concentrationby Serum Phosphate Concentration
rum Phosphate Concentration
.5 mg/dl
657)
3.6–4.0 mg/dl
(n  675)
>4.0 mg/dl
(n  335)
 4.6 73.6 4.4 73.6 4.7
(37.4) 119 (17.6) 33 (10.9)
(86) 592 (88) 291 (87)
(14) 83 (12) 44 (13)
(54.8) 342 (50.7) 206 (61.5)
(12.0) 62 (9.2) 34 (10.1)
(50.1) 323 (47.9) 146 (43.6)
(40.3) 251 (37.2) 136 (40.6)
(3.0) 39 (5.8) 23 (6.9)
 4.6 26.6 4.8 26.2 4.4
 30.6 130.3 32.9 135.3 33.5
 14.6 56.9 14.0 58.2 15.2
 17.2 77.0 17.0 75.4 18.4
 0.36 9.49 0.32 9.5 0.42
 10.1 26.0 12.6 25.4 13.1
 28.7 52.3 24.1 50.5 30.4
L  high-density lipoprotein; LDL  low-density lipoprotein; PTH 
sis, Mitral Annular Calcification,Valve Sclerosis, Mitr Annular Calcification,
Model 1*
OR (95% CI) p Value
Model 2†
OR (95% CI) p Value
1.00 (reference) 1.00 (reference)
1.23 (0.91–1.68) 1.23 (0.90–1.70)
1.47 (1.07–2.02) 1.46 (1.04–2.05)
1.78 (1.23–2.57) 1.64 (1.10–2.43)
1.20 (1.07–1.33) 0.001 1.17 (1.04–1.31) 0.01
1.00 (reference) 1.00 (reference)
1.30 (0.95–1.77) 1.39 (1.01–1.93)
1.34 (0.97–1.84) 1.31 (0.94–1.85)
1.58 (1.11–2.27) 1.62 (1.10–2.38)
1.13 (1.02–1.26) 0.02 1.12 (1.00–1.26) 0.05
1.00 (reference) 1.00 (reference)
1.07 (0.79–1.44) 1.06 (0.77–1.45)
1.35 (0.99–1.84) 1.28 (0.92–1.78)
1.50 (1.05–2.14) 1.32 (0.90–1.92)
1.17 (1.05–1.29) 0.003 1.12 (0.99–1.25) 0.05m Phants
Se
3.1–3
(n 
73.5
246
564
93
360
79
329
265
20
27.1
125.7
54.7
76.5
9.47
25.6
57.9cleroorticMI, LDL, HDL, statin use, vitamin D, PTH, calcium, and site.
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July 12, 2011:291–7 Phosphate and Valve Calcificationcular events independent of kidney function (23–25)
However, none of these previous studies were able to
concomitantly measure and adjust for PTH or vitamin D
levels.
The odds of aortic sclerosis per SD of phosphate are
similar in magnitude to other well-established modifiable
risk factors for aortic valve calcification. Stewart et al. (3)
previously reported small associations with LDL cholesterol
(OR: 1.12, 95% CI: 1.03 to 1.23 [75th vs. 25th percentile]),
hypertension (OR: 1.23, 95% CI: 1.1 to 1.4), and smoking
(OR: 1.3, 95% CI: 1.1 to 1.7) (3). Similar magnitudes for
LDL have been shown in older adults in the Multiethnic
Study of Atherosclerosis. Per 1 SD of LDL cholesterol for
those age 65 to 74 and 75 to 84 years, the OR of aortic valve
calcification was 1.09 and 1.16, respectively (26).
A potential mechanism explaining the relationship be-
tween phosphate and cardiovascular disease is dystrophic
calcification. Animal models with deletion of the gene for
fibroblast growth factor-23, which controls phosphate me-
tabolism, produce phenotypes characterized by hyperphos-
Figure 1 Association of Phosphate and Valve Calcification
Fully adjusted cubic splines showing higher prevalence of aortic valve sclerosis, m
with higher serum phosphate concentrations. Dashed lines indicate 95% confidenc
OR (95% CI) of Aortic Valve Sclerosis, Mitral Annular Calcification,by PTH and 25-OHD Leve sTable 3 OR (95% CI) of Aortic Valve Sclerosis, Mitr Annular Cby PTH and 25-OHD Levels
Aortic Valve Sclerosis
Unadjusted Adjusted* Una
PTH, pg/ml
65 1.00 (reference) 1.00 (reference) 1.00 (r
65 1.08 (0.87–1.35) 1.21 (0.94–1.56) 0.99 (0
25-OHD, ng/ml
30 1.00 (reference) 1.00 (reference) 1.00 (r
15–30 0.93 (0.75–1.16) 0.87 (0.69–1.10) 1.08 (0
15 1.04 (0.76–1.42) 0.83 (0.60–1.17) 1.33 (1*Adjusted for age, sex, race, eGFR, hypertension, diabetes, smoking, BMI, LDL, HDL, statin use, calcium,
Abbreviations as in Tables 1 and 2.phatemia, arteriosclerosis, and ectopic cardiac calcification
that can be reversed with restrictions in dietary phosphorus
(27,28). In vitro studies have shown that phosphate levels
within the normal range can trigger osteogenic transforma-
tion and mineralization of cultured smooth muscle cells
(29). Similar cells that can undergo transdifferentiation into
osteoblast-like cells, myofibroblasts, have been identified in
the aortic valve interstitial layer (30). In smooth muscle
cells, phosphate uptake via the sodium-dependent phos-
phate cotransporter, Pit-1, has been shown to induce
production of osteogenic markers Cbfa1 and osteopontin,
both of which have increased gene expression in calcified
aortic valves (29,31–33).
This study found a stronger association of phosphate level
with AVS as compared with MAC. Conversely, CKD has
more often been associated with MAC than with AVS or
AAC (8,18,34,35). Mineral metabolism disturbances have
been proposed as potential etiologies for valvular and
vascular calcification observed in people with CKD. A
possible explanation is that, compared with previously
nular calcification, and aortic annular calcification
rvals.
Aortic Annular Calcificationcation, a d Aortic Annular Calcification
l Annular Calcification Aortic Annular Calcification
d Adjusted* Unadjusted Adjusted*
ce) 1.00 (reference) 1.00 (reference) 1.00 (reference)
.22) 0.87 (0.68–1.12) 1.01 (0.82–1.25) 0.89 (0.69–1.13)
ce) 1.00 (reference) 1.00 (reference) 1.00 (reference)
.33) 1.00 (0.79–1.26) 1.38 (1.11–1.70) 1.33 (1.06–1.67)
.77) 1.21 (0.87–1.69) 1.33 (0.97–1.80) 1.12 (0.81–1.56)itral an
e inteandlcifi
Mitra
djuste
eferen
.80–1
eferen
.88–1
.01–1and site.
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Phosphate and Valve Calcification July 12, 2011:291–7studied populations, our population had less kidney disease
and no evidence of coronary heart disease. In CKD, mineral
disturbances other than phosphate retention and secondary
hyperparathyroidism can develop, such as reduction in
serum levels of the calcification inhibitor Fetuin-A.
Fetuin-A has been shown to correlate inversely with valve
calcification in patients receiving dialysis (36). Among
patients with coronary heart disease, lower Fetuin-A levels
appear to be associated more strongly with MAC than with
CAVD (37). We were unable to measure Fetuin-A levels in
this study, and the relationship of Fetuin-A with phosphate
levels and cardiac calcification remains a topic for future
investigation.
We had hypothesized that there may be an association
between valve calcification and lower 25-OHD and higher
PTH levels. In kidney failure, disturbances in vitamin D
metabolism cause secondary hyperparathyroidism, which
may accelerate CAVD progression (38). Furthermore, a
hospital-based study in patients with unstable angina with
preserved kidney function found a significant, although
modest, association of more severe CAVD with higher
PTH and lower 25-OHD levels (39). High PTH and low
vitamin D levels may promote ectopic calcification and
inflammation that could lead to cardiovascular disease
(40,41). Population-based studies of people without CKD
have shown that higher PTH and lower 25-OHD levels are
markers for adverse cardiovascular events and are associated
with cardiovascular risk factors (42–44) Additionally, 25-
OHD levels have demonstrated an inverse association with
risk of incident coronary artery calcification (45). It is
possible that elevated PTH and inadequate vitamin D levels
promote atherosclerosis but not valve calcification. Alterna-
tively, the lack of association in our study may be related to
the exclusion of people with known cardiovascular disease.
Study strengths. Strengths of our study include a large
sample size from a well-defined community-based cohort
with standardized echocardiography measures and risk fac-
tor assessment. In addition, we were able to adjust our
Figure 2 Fully Adjusted Prevalence of Aortic Valve Sclerosis
There was no association of parathyroid hormone (PTH) and 25-hydroxyvitamin D
levels with aortic valve sclerosis. Dashed lines indicate 95% confidence
intervals.models for serum cystatin C levels, which more preciselycharacterize kidney function in older adults than does serum
creatinine, the traditional serological marker of eGFR.
Study limitations. First, the study included only single
measurements of phosphate, PTH, and 25-OHD, all of
which exhibit biological variation over time and all of which
were performed 2 years before the echocardiograms. How-
ever, these limitations likely would lead to nondifferential
misclassification that would attenuate associations toward
the null hypothesis. A similar limitation includes not being
able to account for dietary phosphate intake in this analysis.
However, participants were instructed to fast, and serum
phosphate levels are tightly regulated, even in the postpran-
dial state (46,47). Further, because longitudinal echocardio-
grams were not available, this was a cross-sectional study
that reported prevalence, not incidence, of AVS, AAC, and
MAC. Additionally, because echocardiograms do not allow
precise quantification of calcification severity, relationships
of phosphate dose response to calcification severity could
not be assessed. Another limitation of this observational
study is the possibility that unmeasured confounders might
explain observed associations of phosphate with AVS and
AAC. Further, phosphate levels were measured only in
CHS participants without known cardiovascular disease at
year 5, resulting in survival bias in the study population.
Finally, because this was an observational study, and not
designed to assess the effect of phosphate levels on clinical
outcomes, the results should not be used to guide clinical
decision making in CAVD.
Conclusions
The findings of this study, along with the role of phosphate
in ectopic calcification, suggest that phosphate may be a
biologically plausible, novel risk factor for CAVD. If these
results are confirmed, they may lead to studies to determine
whether novel therapies targeting phosphate metabolism
might alter the development or progression of CAVD.
Accordingly, the role of phosphate in CAVD warrants
further study.
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